The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1096
Nebulized Budesonide For Asthma in Children
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nebulized Budesonide For Asthma in Children
The FDA has approved a nebulized suspension of the corticosteroid budesonide for maintenance treatment of persistent asthma in children one to eight years old.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nebulized Budesonide For Asthma in Children
Article code: 1096b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.